Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
152.80    -0.20 (-0.13%)
Bid:
153.20
Ask:
153.60
Spread: 0.40 (0.261%)
Market Cap: £874.50m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

Third Quarter Trading Update

31 Oct 2023 07:00

RNS Number : 7710R
Elementis PLC
31 October 2023
 

 

31 October 2023

 

 

 

Elementis plc

Third Quarter Trading Update

 

Outlook unchanged, delivering resilient performance in line with expectations.

Elementis plc ("Elementis" or the "Group"), a global specialty chemicals company, today issues its scheduled trading update for the three months ended 30 September 2023 ("the quarter").

 

Third quarter business performance

The Group delivered a resilient performance as expected, in continued challenging market conditions, with Q3 revenue at a similar level to that seen in the first and second quarters. Against the prior year period, revenue was down 5% (down 7% on a constant currency basis), with lower revenues across both business segments. We remain focused on self-help actions including new business opportunities, price management and cost discipline.

 

Personal Care sales in the quarter were sequentially stable, but below a strong prior year period. We saw continued strong growth in Asia.

Performance Specialties delivered resilient performance as continued market related volume weakness across both Coatings and Talc was partially offset by pricing and mix benefits.

· Coatings sales were sequentially stable, though below the prior year period, with Asia showing modest improvement compared with the previous two quarters.

 

· Talc continued to benefit from self-help actions, with higher profit compared to the weak prior year period. We continue to focus on financial turnaround and pursuing new business opportunities.

 

Outlook

The Group is well positioned to deliver full-year financial performance in line with expectations, despite continuing weakness in underlying macro-economic conditions. Leverage reduction remains on track supported by continued inventory improvement in Q3.

 

Paul Waterman, CEO of Elementis, said:

"Elementis delivered a resilient third quarter performance, as we continued to focus on product innovation and customer relationships, while maintaining strong cost discipline. Despite the industry and macroeconomic conditions remaining uncertain, we remain well positioned to take advantage of growth opportunities across our market segments.

Following the sale of Chromium earlier this year, Elementis is now a focused specialty chemicals business. We look forward to providing detail about our go forward strategy at the upcoming Capital Markets Day."

 

Capital Markets Day

Elementis is hosting a Capital Markets Day on 14th November, at WPP, Sea Containers House, London, starting at 2.00 pm GMT.

Webcast will be available for those unable to attend. Registration for physical and virtual attendance is required, and can be accessed via the link Viewing "Elementis Capital Markets Day " (investis-live.com).

 

Enquiries

Investors: Eva Hatfield, Elementis plc Tel: +44 7553 340380

Press: Martin Robinson/Olivia Peters, Teneo Tel: +44 (0) 20 7353 4200

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKKBBFBDDOKN
Date   Source Headline
8th Jun 20265:14 pmRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSCommencement of share buyback programme
2nd Jun 20267:00 amRNSSale of Pharma business & intended buyback launch
1st Jun 20269:58 amRNSTotal Voting Rights
5th May 20265:26 pmRNSHolding(s) in Company
1st May 20269:59 amRNSTotal Voting Rights
29th Apr 20263:47 pmRNSResult of AGM
29th Apr 20267:00 amRNSFirst quarter trading update
8th Apr 20264:14 pmRNSDirector/PDMR Shareholding
7th Apr 20263:06 pmRNSDirector/PDMR Shareholding
1st Apr 202610:18 amRNSTotal Voting Rights
30th Mar 20265:06 pmRNSCorrection - Admission to Trading
30th Mar 20261:58 pmRNSAdmission to Trading
26th Mar 202612:09 pmRNSNotice of AGM and Annual Report & Accounts
19th Mar 20267:00 amRNSDirectorate change
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
11th Mar 20263:18 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:40 pmRNSDirector/PDMR Shareholding
10th Mar 20263:39 pmRNSDirector/PDMR Shareholding
9th Mar 20265:14 pmRNSHolding(s) in Company
5th Mar 20265:11 pmRNSBlocklisting Interim Review
5th Mar 20264:57 pmRNSPreliminary Results - Correction
5th Mar 20267:00 amRNSPreliminary Results
2nd Mar 202610:00 amRNSTotal Voting Rights
25th Feb 20264:22 pmRNSDirectorate change
2nd Feb 202610:05 amRNSTotal Voting Rights
21st Jan 20267:00 amRNSTrading Update
2nd Jan 202611:10 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSConfirmation of Board changes
2nd Jan 20267:00 amRNSConfirmation of Board changes
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
24th Dec 202510:25 amRNSDirector/PDMR Shareholding
15th Dec 20257:00 amRNSCompletion of Buyback programme
15th Dec 20257:00 amRNSTransaction in Own Shares
11th Dec 20255:35 pmRNSTransaction in Own Shares
10th Dec 20256:12 pmRNSTransaction in Own Shares
9th Dec 20255:55 pmRNSTransaction in Own Shares
8th Dec 20255:52 pmRNSTransaction in Own Shares
8th Dec 20257:00 amRNSTransaction in Own Shares
4th Dec 20256:06 pmRNSTransaction in Own Shares
3rd Dec 20255:28 pmRNSTransaction in Own Shares
3rd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20255:49 pmRNSTransaction in Own Shares
28th Nov 20255:49 pmRNSTransaction in Own Shares
27th Nov 20255:40 pmRNSTransaction in Own Shares
27th Nov 20257:00 amRNSTransaction in Own Shares
26th Nov 20257:00 amRNSElementis acquires personal care specialist
25th Nov 20255:44 pmRNSTransaction in Own Shares
24th Nov 20256:01 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.